Your browser doesn't support javascript.
loading
Modeling long-term tumor growth and kill after combinations of radiation and radiosensitizing agents.
Cardilin, Tim; Almquist, Joachim; Jirstrand, Mats; Zimmermann, Astrid; Lignet, Floriane; El Bawab, Samer; Gabrielsson, Johan.
Afiliación
  • Cardilin T; Fraunhofer-Chalmers Centre, Chalmers Science Park, Gothenburg, Sweden. tim.cardilin@fcc.chalmers.se.
  • Almquist J; Department of Mathematical Sciences, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden. tim.cardilin@fcc.chalmers.se.
  • Jirstrand M; Fraunhofer-Chalmers Centre, Chalmers Science Park, Gothenburg, Sweden.
  • Zimmermann A; Fraunhofer-Chalmers Centre, Chalmers Science Park, Gothenburg, Sweden.
  • Lignet F; Translation Innovation Platform Oncology, Merck Healthcare KGaA, Darmstadt, Germany.
  • El Bawab S; Translational Medicine, Quantitative Pharmacology, Merck Healthcare KGaA, Darmstadt, Germany.
  • Gabrielsson J; Translational Medicine, Quantitative Pharmacology, Merck Healthcare KGaA, Darmstadt, Germany.
Cancer Chemother Pharmacol ; 83(6): 1159-1173, 2019 06.
Article en En | MEDLINE | ID: mdl-30976845
ABSTRACT

PURPOSE:

Radiation therapy, whether given alone or in combination with chemical agents, is one of the cornerstones of oncology. We develop a quantitative model that describes tumor growth during and after treatment with radiation and radiosensitizing agents. The model also describes long-term treatment effects including tumor regrowth and eradication.

METHODS:

We challenge the model with data from a xenograft study using a clinically relevant administration schedule and use a mixed-effects approach for model-fitting. We use the calibrated model to predict exposure combinations that result in tumor eradication using Tumor Static Exposure (TSE).

RESULTS:

The model is able to adequately describe data from all treatment groups, with the parameter estimates taking biologically reasonable values. Using TSE, we predict the total radiation dose necessary for tumor eradication to be 110 Gy, which is reduced to 80 or 30 Gy with co-administration of 25 or 100 mg kg-1 of a radiosensitizer. TSE is also explored via a heat map of different growth and shrinkage rates. Finally, we discuss the translational potential of the model and TSE concept to humans.

CONCLUSIONS:

The new model is capable of describing different tumor dynamics including tumor eradication and tumor regrowth with different rates, and can be calibrated using data from standard xenograft experiments. TSE and related concepts can be used to predict tumor shrinkage and eradication, and have the potential to guide new experiments and support translations from animals to humans.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fármacos Sensibilizantes a Radiaciones / Modelos Biológicos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Chemother Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Fármacos Sensibilizantes a Radiaciones / Modelos Biológicos / Neoplasias Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Cancer Chemother Pharmacol Año: 2019 Tipo del documento: Article País de afiliación: Suecia